FDA Orange Book · active-ingredient family
Metaxalone
Metaxalone: 2 brands, 8 generics; first approved Aug 30, 2002; generic available.
Generic availableHas discontinued products
Generic status & protection
Generic available: 8 ANDA applications approved.
Earliest patent expiry
Brands (NDA)
2
Generics (ANDA)
8
Listed patents
3
Next patent expiry
Feb 06, 2026
9 mo ago
Brand (NDA) products
Originator applications
- METAXALONERLDRSPRIMUS PHARMSNDA 0225032015
Approved strengths under this FDA application. Strength Dosage form Route Status TE 640MG TABLET ORAL Rx - - SKELAXINRLDKING PHARMSNDA 013217-2 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 400MG TABLET ORAL Discontinued - 800MG TABLET ORAL Discontinued -
Generic (ANDA) products (8)
Abbreviated applications
- METAXALONEINGENUS PHARMS LLCANDA 2138362020
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Discontinued - - METAXALONESCIEGEN PHARMSANDA 20746620202 strengths
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Rx AB 400MG TABLET ORAL Rx AB - METAXALONERISINGANDA 2087742018
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Discontinued - - METAXALONEACTAVIS LABS FL INCANDA 2036952017
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Rx AB - METAXALONELANNETT CO INCANDA 2047702016
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Rx AB - METAXALONEMOUNTAINANDA 0404862015
Approved strengths under this FDA application. Strength Dosage form Route Status TE 400MG TABLET ORAL Rx AB - METAXALONERSAMNEAL PHARMSANDA 2033992013
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Rx AB - METAXALONESANDOZANDA 0404452010
Approved strengths under this FDA application. Strength Dosage form Route Status TE 800MG TABLET ORAL Rx AB
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Listed patents
Orange Book patent file
| Patent | Expires | In | Type |
|---|---|---|---|
| 7122566 | 9 mo ago | U-915 | |
| 11918559 | in 12 yr 11 mo | Product | |
| 12485111 | in 16 yr 10 mo | ProductU-4453 |
Approval history
FDA approval span
First approval
24 yr 6 mo ago
Most recent approval
6 yr 1 mo ago
Approvals span 2002–2020 across 10 FDA applications.
Brand (NDA) 220%
Generic (ANDA) 880%
Metaxalone: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Metaxalone
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo